



Data-Rich Phenomena - Modelling, Analysing & Simulation Using Partial Differential Equations:


**Anonymised Electronic Health Record Data: Uses, Strengths and Weaknesses** 

Tim Williams, CPRD, 14th December 2015






## The Clinical Practice Research Datalink



## Potential of using health records in research

## NHS 'cradle to grave cohort' of UK population

- Enables research at scale not otherwise possible
- Linkage across health records and other datasets
- Real world settings
- Answer questions needing large datasets
  - Rare conditions
  - Replicate smaller research studies
- Retrospective and prospective
- Long term follow up added value
- Cost effective



### What is CPRD?

- A longitudinal database of anonymised primary care records linked to other heath data sets
- UK Government funded MHRA and NIHR


England, Scotland, Wales and NI

28 years of data collection

Total >20 million lives

Current data collection

>5 million patients currently registered with 620 GP practices




October 2015

March 2012

# Data collected from primary care record

#### 1.8 billion consultations including

- Drug exposure
- Diagnoses and symptoms
- Referrals
- Laboratory tests
- Vaccination history
- Demographic data
- Full coded record
- No free text
- Patient identifiers removed at source





# Data linkage

## National datasets regularly linked to primary care data

- Mortality
- Hospital Episode Statistics (HES)
  - Inpatient, Outpatient and A&E data
- National Cancer Registry
- Diagnostic Imaging Dataset (DIDs)
- Townsend score
- Index of Multiple Deprivation (IMD)

## Bespoke data linkage for individual studies

Eg The Million Women Study, ALSPAC

## Research Applications of EHRs

- Drug usage and patterns Pharmacoepidemiology
- Drug safety Pharmacovigiliance
- Effectiveness and cost effectiveness
- Epidemiology risks, incidence, prevalence
- Public health immunisation, disease surveillance
- Health services quality of care, resource planning, clinical decisions
- Locate potentially eligible patients for clinical trials
- Policy evaluation

# Pubic health impact

2 CPRD studies in the shortlisted final 5 for the BMJ UK Research Paper of the Year 2014



ORIGINAL ARTICLE

Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation

René Schade, M.D., Frank Andersohn, M.D., Samy Suissa, Ph.D., Wilhelm Haverkamp, M.D., Ph.D., and Edeltraut Garbe, M.D.,



Home > Clinical > Prescribing

One in seven GP-prescribed antibiotic courses fails, study finds

26 September 2014 | By Caroline Price

## THE LANCET

Volume 364, Issue 9438, 11-17 September 2004, Pages 963-969


MMR vaccination and pervasive developmental disorders: a case-control study



Medscape Medical News > Neurology

Mega Hypertension Study Defines Risk for 12 CVD Outcomes

Sue Hughes June 11, 2014



**Suspected cancer Clinical Guidance** 

For some cancers exclusively drew evidence from CPRD research


## Diagnosis & Treatment of bacterial STIs

**Question**: Contribution of GPs to the diagnosis and management of STIs, & whether treatment complied with national guidelines


**Data used**: over 200,000 EHRs from 2000-2011 patients with chlamydia or gonorrhoea, compared to >1.3m records from GU clinics

Result: ~50% of gonorrhoea patients were treated with antibiotic no longer recommended by guidelines.

Wetten et al, BMJ Open 2015;5:e007776



# Rate of referral to rheumatology: Fibromyalgia cases and matched controls



## CPRD Real World studies across drug development pipeline

File & Early Late Post-Research development development Launch MA Drug utilisation & Epidemiology, incidence / prevalence prescribing Pharmacovigilance, Standard of care delivery Pharmacoepidemiology Post marketing Patient referral for intervention studies and clinical pragmatic studies trials Clinical trials feasibility - patient eligibility


# Antiepileptic Drugs utilisation over 15 years

Utilisation trends in UK 1993-2008

Cohort of 63,586 patients - total 361,207 person-years data


Trends for 21 different medicines
Accuracy of prescription records

Changes generally consistent with national recommendations for prescribing in epilepsy current during this period.



# Dose titration

Mean prescription strength over time in a group of patients using buprenorphine patches for chronic pain




## Exposure to HPV-16/18-vacc & spontaneous abortion

- HPV-16/18-vaccine indicated for women (15-25yo) for prevention of cervical cancer
- Analysis of clinical trial data suggested increased risk of spontaneous abortion when LMP occurred -30 to +45 days from exposure

CPRD primary care data for 1,046 HPV-vaccinated women 15-25yo, 09/2008-06/2011. **Results:** Increased HR (one or two doses) vs non-exposed, not significantly

- ➤ No overall increase in spontaneous abortion in women inadvertently vaccinated
- Women who are pregnant / trying to get pregnant advised to postpone vaccination



# Pioglitazone safety study



## Bladder cancer risk in T2DM patients on pioglitazone

#### Bladder cancer risk for never vs. ever exposed to Pioglitazone

Cohort	Q-statistic for he	Events	
size	I^2 (total heterogen	Ever vs. Never	
18,794	FIN	0.56 [ 0.31 ,	1.00] 24 vs. 40
3,712	SWE	4.27 [ 1.26 ,	14.46 ] 15 vs. 4
11,408	CPRD GOLD	1.04 [ 0.51 ,	2.11 ] 24 vs. 26
12,109	CPRD GOLD-HES	0.65 [ 0.35 ,	1.21 ] 30 vs. 52
7,491	NL HOSP-PHARM	1.71 [ 0.94 ,	3.12] 33 vs. 26
2,823	NL GP	1.23 [ 0.42 ,	3.63 ] 10 vs. 10
	meta-analyses (random-effect)	1.10 [ 0.65 ,	1.85]
	meta-analyses (fixed-effect)	0.99 [ 0.74 ,	1.32]
56,337	pooled data	0.99[0.75,	1.30 ] 130 vs. 153
		0.25 1.00 4.00 16.00	
		hazard ratio	

#### Risk of Mortality and Major Cardiovascular Events in Antipsychotics

Data: Primary care, HES, ONS death data and free-text.

**Cohort:** 183,392 antipsychotic users, 544,726 general population controls, and 193,920 psychiatric nonusers. Outcomes included all cause mortality, cardiac mortality and sudden cardiac death.

#### **Results:**

Outcome	Exposure	Age & sex adjusted Relative Risk [95% CI)	Fully adjusted Relative Risk [95% CI)
All Cause Mortality	General population	Reference	Reference
	Current use	2.98 [2.93-3.03]]	2.72[2.67-2.77]
	Psychiatric non-users	Reference	Reference
	Current use	2.15[2.10-2.21]	1.75[1.64-1.87]
Cardiac Mortality	General population	Reference	Reference
	Current use	2.01[1.90-2.10]	1.83[1.74-193]
	Psychiatric non-users	Reference	Reference
	Current use	1.62 1.52 -1.74]	1.72[1.42-2.07]

**Conclusion:** Antipsychotic users are at increased risk of cardiac mortality, all-cause mortality, and SCD compared to a psychiatric nonuser cohort.

# Trial feasibility & protocol optimisation



#### Search Results

#### Patient Count: 15,816 found

North East: 128 found

North West: 3,136 found

Yorkshire & The Humber: 350 found

East Midlands: 410 found West Midlands: 1,522 found

East of England: 1,604 found

South West: 629 found

South Central: 1,444 found


London: 1,920 found

South East Coast: 1,409 found

Northern Ireland: 1,333 found

Scotland: 1,744 found

Wales: 187 found





# "Explanatory" vs "Pragmatic" trials

Explanatory	Pragmatic
"Can this intervention work under ideal conditions?"	"Does this intervention work under usual conditions?,"
Maximise internal validity	Maximise external validity
Selective recruitment: high risk, highly responsive patients with high compliance	Not selective: include all patients with condition of interest
Intervention: tightly controlled, applied by highly trained trial personnel and carefully monitored	Flexible: intervention applied by usual range of providers and settings
Control intervention: carefully designed to maximise change of detecting benefit of experimental intervention	Comparison is with normal standard of care
Follow-up: intensive visit schedule, extensive data collection, shorter duration, all patients	No formal follow-up. Use routine data(bases) to detect outcomes (including adverse)
Adherence & protocol deviations: closely monitored	Minimal monitoring.
Analysis: additional per protocol and subgroup analyses to identify maximum achievable treatment effect	Intention to treat analysis only

J Clin Epidemiol 2009:65;464-75



# Challenges of pharmacoepidemiology with databases










# Same database (CPRD), different answers: Statins and fracture risk

	[1] Meier et al	[2] van Staa <i>et al</i>
	Adjusted OR	Adjusted OR
	(95% CI)	(95% CI)
	Selected population	Entire population
Any fracture	0.55 (0.44-0.69)	1.01 (0.88-1.16)
Femur/hip	0.12 (0.04-0.41)	0.59 (0.31-1.13)
Vertebral	0.14 (0.02-0.88)	1.15 (0.62-2.14)

[1] JAMA 2000;283:3205-10. [2] JAMA 2001;285:1850-55


# Same study design: different databases



Evaluating the Impact of Database Heterogeneity on Observational Study Results. Madigan D et al. Am. J. Epidemiol. 2013; 178(4): 645-651.

## Database study fails to replicate RCT findings:

Spironolactone in heart failure: effect on mortality



"the clinical decision to treat used additional important information on severity of heart failure that the propensity score did not capture"

"The challenge of a latent function such as confounding by indication is that it (by definition) cannot be measured directly but only tangentially through its effects, if it is recognised at all."

Nick Freemantle et al. BMJ 2013;347:bmj.f6409

# Bias and Confounding

- Confounding by indication can occur if some unmeasured variable is associated with both the outcome and with the study treatment
- Measuring disease severity can be challenging, and lead to confounding if study treatment is preferentially given to patients with more (or less) severe disease

# Summary

- The CPRD and other EHR databases key resource for generating evidence on:
  - Disease epidemiology and Drug utilisation
  - Drug safety / Adverse drug reactions
  - Health outcomes and resource utilisation
  - Health service planning
- As with any non-randomised study, observational studies using databases are susceptible to bias and confounding.
- Large scale randomised studies embedded within EHR databases combine some of the advantages of each study types